Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.35 -2.9%	$1.29	$1.05 ▼ $10.16	$42.47M	1.65	253,439 shs	213,026 shs
BRNS Barinthus Biotherapeutics	$1.26 -1.6%	$1.19	$0.64 ▼ $2.92	$50.02M	-0.73	238,323 shs	13,541 shs
LVTX LAVA Therapeutics	$1.52 -1.3%	$1.40	$0.85 ▼ $2.09	$39.98M	0.5	168,142 shs	192,254 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	+8.87%	+2.27%	+17.39%	-80.77%
BRNS Barinthus Biotherapeutics	0.00%	-6.34%	-17.97%	+32.94%	-5.64%
LVTX LAVA Therapeutics	0.00%	-0.65%	+8.57%	+21.60%	-14.12%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.8288 of 5 stars	3.5	3.0	0.0	0.0	1.9	2.5	0.6
BRNS Barinthus Biotherapeutics	2.9352 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
LVTX LAVA Therapeutics	2.1975 of 5 stars	3.0	5.0	0.0	0.0	2.9	0.0	0.0
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.57	1,201.59% Upside
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	139.04% Upside
LVTX LAVA Therapeutics	2.00	Hold	$2.69	76.64% Upside
NTEC Intec Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTEC, ACRV, LVTX, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	3.38	N/A	N/A	$3.23 per share	0.39
LVTX LAVA Therapeutics	$11.98M	3.34	N/A	N/A	$1.06 per share	1.43
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.25	N/A	N/A	N/A	N/A	-50.78%	-46.08%	N/A
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	0.00	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.05	N/A	N/A	N/A	N/A	-106.29%	-38.24%	8/19/2025 (Estimated)
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A

Latest NTEC, ACRV, LVTX, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.55	+$0.02	-$0.55	N/A	N/A
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	10.31	10.31
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
LVTX LAVA Therapeutics	N/A	10.78	10.78
NTEC Intec Pharma	N/A	2.34	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
BRNS Barinthus Biotherapeutics	25.20%
LVTX LAVA Therapeutics	N/A
NTEC Intec Pharma	22.37%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	8.50%
BRNS Barinthus Biotherapeutics	8.00%
LVTX LAVA Therapeutics	9.50%
NTEC Intec Pharma	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.46 million	28.78 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	37.11 million	N/A
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
NTEC Intec Pharma	40	898,000	N/A	Optionable

NTEC, ACRV, LVTX, and BRNS Headlines

Recent News About These Companies

INDP stock touches 52-week low at $0.78 amid market challenges

February 12, 2025 | msn.com

Indaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last year

November 13, 2024 | markets.businessinsider.com

FinTechOn 2024: FinTech Associations from 14 Asian Economies Sign MOU to Enhance Collaborations in Anti-Fraud

November 5, 2024 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (XFOR)

September 21, 2024 | finance.yahoo.com

Intec Pharma shares dive after Parkinson's trial failure

September 9, 2024 | pharmaphorum.comP

INDP Indaptus Therapeutics, Inc.

August 23, 2024 | seekingalpha.com

Q1 Results, Aug. 14: Ola Electric, Glenmark, HAL To Declare Earnings Today

August 14, 2024 | ndtvprofit.comN

Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical Developments

August 13, 2024 | markets.businessinsider.com

Morepen Laboratories Ltd Company Summary

July 22, 2024 | indiainfoline.comI

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In

May 14, 2024 | msn.com

Minebea Intec Opens Technical Center

May 10, 2024 | powderbulksolids.comP

Buy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical Advancements

May 10, 2024 | markets.businessinsider.com

Rheinmetall’s MS Motorservice Implements State-of-the-Art High-Bay Storage System in Neuenstadt

April 17, 2024 | news.europawire.euN

Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising Developments

March 6, 2024 | markets.businessinsider.com

Stocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and more

February 18, 2024 | msn.com

Chhattisgarh education minister calls for expansion of central schools in the state

February 2, 2024 | msn.com

The 2024 Chicago Titan 100: Here's who made the list

November 12, 2023 | dailyherald.comD

H.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)

August 15, 2023 | markets.businessinsider.com

NGENF - NervGen Pharma Corp.

June 15, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTEC, ACRV, LVTX, and BRNS Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.35 -0.04 (-2.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.03 (+2.22%)

As of 08/15/2025 07:50 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Barinthus Biotherapeutics NASDAQ:BRNS

$1.25 -0.02 (-1.64%)

Closing price 08/15/2025 03:36 PM Eastern

Extended Trading

$1.24 -0.01 (-1.20%)

As of 08/15/2025 06:41 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

LAVA Therapeutics NASDAQ:LVTX

$1.52 -0.02 (-1.30%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.52 +0.00 (+0.33%)

As of 08/15/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Intec Pharma NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time